👏 This clip never gets old. Get the most out of your efforts to take this path to market.
Is FDA Breakthrough Device Designation worth it? You might be surprised by the answer. During this LSI USA '24 panel, the consensus among panelists was that the FDA Breakthrough Device Designation may not be as beneficial as it seems. However, if you still choose to pursue it, the panelists offer valuable advice for those considering this path. Tune into the full panel to hear the advice and nuance from innovators, attorneys, and regulatory experts who have navigated the strategic and operational challenges of winning FDA Breakthrough Designation. The full panel, “FDA Breakthrough Designation: ROI and Considerations With Shifts in Coverage” is available on our website and YouTube channel. Featured panelists: • Etienne Nichols (Moderator), Head of Industry Insights & Education at Greenlight Guru • Kwame Ulmer, Managing Partner at MedTech Impact Partners • Carolina Aguilar, Co-Founder & CEO of INBRAIN Neuroelectronics • Nathan Beaver, Partner at Foley & Lardner LLP • Lishan Aklog, MD is Chairman & CEO at Lucid Diagnostics As we look back at highlights from LSI USA '24, we're gearing up for an even better LSI USA '25. Apply on our website today to join top Medtech and Healthtech leaders in Dana Point, California, this March 17-21.